Royalty Pharma PLC expected to post earnings of $1.01 a share - Earnings Preview

Royalty Pharma

13/02/2024 13:44

* Royalty Pharma PLC  RPRX.OQ   RPRX.O  is expected to show
a rise
in quarterly revenue when it reports  results on February 15 for
the period ending December 31 2023
    * The New York City-based  company is expected to report a
22.2% increase in revenue to $691.646 million from $566 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Royalty Pharma PLC is
for
earnings of $1.01 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Royalty
Pharma
PLC is $45.00​, above​ its last closing price of $29.05. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  0.77        0.76       0.79      Beat    4.5
 Jun. 30 2023  0.81        0.81       0.84      Beat    4
 Mar. 31 2023  1.30        1.27       1.60      Beat    25.7​
 Dec. 31 2022  1.39        1.47       1.56      Beat    5.9
 ​​Sep.        0.71        0.72       0.72      Met     0.5
 30 2022                                                
 Jun. 30 2022  0.79        0.78       0.79      Beat    1.1​
 Mar. 31 2022  0.74        0.73       0.60      Missed  -18
 Dec. 31 2021  0.77        0.78       0.80      Beat    3.2
 This summary was machine generated February 13 at 13:44 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)